Amoxapine Shortage: A Provider Briefing for 2026

The ongoing Amoxapine shortage has created real challenges for providers managing patients on this tricyclic antidepressant. With Teva Pharmaceuticals as the sole US manufacturer and intermittent supply disruptions since August 2024, prescribers need to stay informed about current availability, clinical alternatives, and tools to support patient access.

This briefing covers the key information you need to manage your Amoxapine patients effectively in 2026.

Shortage Timeline

The Amoxapine shortage has evolved over the past 18 months:

• August 2024: The American Society of Health-System Pharmacists (ASHP) first reported the Amoxapine Tablets shortage. The initial report cited limited supply of 50 mg tablets from Teva Pharmaceuticals, the sole US manufacturer.
• Late 2024: Supply disruptions expanded intermittently to other strengths (25 mg, 100 mg, 150 mg). No additional manufacturers entered the market.
• April 2025: ASHP updated the shortage listing. Teva continued as the only source; no estimated resolution date was provided.
• Early 2026: The shortage persists. Some strengths are intermittently available, but consistent nationwide supply has not been restored. The FDA drug shortage database continues to track the situation.

Prescribing Implications

The shortage has several clinical implications for providers:

Continuity of Care Risk

Patients on stable Amoxapine regimens face the risk of involuntary treatment interruptions. Abrupt discontinuation of a TCA can result in withdrawal symptoms (nausea, headache, malaise, irritability) and clinical deterioration, including depressive relapse.

Dose and Strength Flexibility

Not all strengths are equally affected at any given time. Consider prescribing alternative strengths when the prescribed dose is unavailable:

• If 50 mg tablets are out of stock, prescribe 25 mg tablets (two per dose)
• If 100 mg tablets are unavailable, consider 50 mg tablets (two per dose) or 150 mg tablets with appropriate dose adjustment
• Amoxapine is available in 25 mg, 50 mg, 100 mg, and 150 mg tablets

Proactive Patient Communication

Patients may not inform you about fill difficulties until they've already run out. Consider proactively asking patients on Amoxapine about their ability to fill prescriptions and having contingency plans in place.

Current Availability Picture

Availability varies significantly by region, pharmacy type, and tablet strength. Key points:

• Teva Pharmaceuticals remains the sole US manufacturer of generic Amoxapine tablets
• The brand product Asendin has been discontinued in the US market and is not available
• Chain pharmacies (CVS, Walgreens, Rite Aid) are often the first to deplete stock during shortages due to centralized allocation
• Independent pharmacies may have access to different wholesaler channels and can sometimes source Amoxapine when chains cannot
• Compounding pharmacies can prepare Amoxapine from USP-grade raw material if commercial product is unavailable

Cost and Access Considerations

Cost should be factored into treatment planning, especially for uninsured or underinsured patients:

• Retail cash price: $31–$80 for 30 tablets, depending on strength
• With discount coupons: $11–$19 for 30 tablets (100 mg) through services like SingleCare, WellRx, or GoodRx
• Insurance coverage: Typically covered as a Tier 2 generic; copays generally $5–$25
• Patient assistance programs: No manufacturer-specific PAP exists. Third-party programs (NiceRx, NeedyMeds, RxAssist) may assist eligible patients

For detailed pricing information to share with patients, see our patient-facing guide on how to save money on Amoxapine.

Clinical Alternatives

When Amoxapine cannot be obtained, the following TCA alternatives should be considered based on the patient's clinical profile:

Nortriptyline (Pamelor)

Secondary amine TCA with primarily noradrenergic activity. Generally better tolerated than tertiary amine TCAs. Therapeutic drug monitoring is available (target level: 50–150 ng/mL). Does not have Amoxapine's dopamine-blocking properties. Typical dose: 25–150 mg/day.

Desipramine (Norpramin)

Most norepinephrine-selective TCA. Lowest anticholinergic burden in the class. Preferred when minimizing sedation and autonomic side effects is a priority. Therapeutic drug monitoring available (target level: 100–300 ng/mL). Typical dose: 100–200 mg/day.

Doxepin

TCA with strong antihistamine and sedating properties. Useful when depression is accompanied by significant insomnia. Higher anticholinergic burden. Also FDA-approved for insomnia at low doses (3–6 mg). Typical antidepressant dose: 75–150 mg/day.

Imipramine (Tofranil)

Tertiary amine TCA with dual norepinephrine and serotonin reuptake inhibition. Extensive evidence base. Higher side effect profile. Typical dose: 75–200 mg/day.

Key consideration: Amoxapine's D2/D4 receptor antagonism provides mild antipsychotic properties. For patients whose depression includes psychotic features, an alternative TCA plus a low-dose atypical antipsychotic may be needed to replicate this effect.

For a patient-friendly overview of alternatives, refer patients to our guide on alternatives to Amoxapine.

Tools and Resources for Providers

Several tools can help you and your patients navigate the shortage:

• Medfinder for Providers — Search pharmacy availability for Amoxapine and other medications in shortage. Help patients locate in-stock pharmacies quickly.
• ASHP Drug Shortage Database — Monitor shortage status updates and manufacturer communications
• FDA Drug Shortage Database — Track official shortage listings and estimated resupply dates
• State Board of Pharmacy — Some states have emergency dispensing provisions during shortages that may allow pharmacists more flexibility

Looking Ahead

The Amoxapine shortage reflects broader vulnerabilities in the US generic drug supply chain:

• Single-source risk: When only one manufacturer produces a medication, any disruption can create a nationwide shortage
• Economic disincentives: Low-volume, low-margin generics like Amoxapine offer minimal financial incentive for new market entrants
• No near-term resolution: As of early 2026, no additional manufacturers have announced plans to produce Amoxapine in the US

Providers should plan for the possibility that Amoxapine supply will remain inconsistent throughout 2026. Having a documented alternative treatment plan for each Amoxapine patient is prudent practice.

Final Thoughts

The Amoxapine shortage requires proactive management from prescribers. Know which patients are on Amoxapine, check in regularly about fill status, and have alternative treatment plans ready. Tools like Medfinder for Providers can streamline the process of locating available stock for your patients.

For additional clinical guidance, see our provider's guide on how to help your patients find Amoxapine in stock and our provider-focused savings guide on how to help patients save money on Amoxapine.